CN116419746A - 右旋普拉克索用于治疗中度至重度哮喘的用途 - Google Patents

右旋普拉克索用于治疗中度至重度哮喘的用途 Download PDF

Info

Publication number
CN116419746A
CN116419746A CN202180068016.4A CN202180068016A CN116419746A CN 116419746 A CN116419746 A CN 116419746A CN 202180068016 A CN202180068016 A CN 202180068016A CN 116419746 A CN116419746 A CN 116419746A
Authority
CN
China
Prior art keywords
asthma
subject
dexpramipexole
eosinophil
phenotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068016.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·P·普拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aretai Treatment Co
Original Assignee
Aretai Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aretai Treatment Co filed Critical Aretai Treatment Co
Publication of CN116419746A publication Critical patent/CN116419746A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180068016.4A 2020-08-05 2021-08-05 右旋普拉克索用于治疗中度至重度哮喘的用途 Pending CN116419746A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063061226P 2020-08-05 2020-08-05
US63/061,226 2020-08-05
US202163136933P 2021-01-13 2021-01-13
US63/136,933 2021-01-13
US202163147024P 2021-02-08 2021-02-08
US63/147,024 2021-02-08
US202163174938P 2021-04-14 2021-04-14
US63/174,938 2021-04-14
PCT/US2021/044719 WO2022031956A1 (en) 2020-08-05 2021-08-05 Use of dexpramipexole for the treatment of moderate to severe asthma

Publications (1)

Publication Number Publication Date
CN116419746A true CN116419746A (zh) 2023-07-11

Family

ID=80115688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068016.4A Pending CN116419746A (zh) 2020-08-05 2021-08-05 右旋普拉克索用于治疗中度至重度哮喘的用途

Country Status (11)

Country Link
US (4) US20220040154A1 (https=)
EP (1) EP4192453A4 (https=)
JP (1) JP2023538278A (https=)
KR (1) KR20230067604A (https=)
CN (1) CN116419746A (https=)
AU (1) AU2021322255A1 (https=)
CA (1) CA3186844A1 (https=)
CL (1) CL2023000296A1 (https=)
IL (1) IL300357A (https=)
MX (1) MX2023001140A (https=)
WO (1) WO2022031956A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260119B (zh) * 2022-07-26 2023-02-10 山东京卫制药有限公司 一种普拉克索昔萘酸盐及其药物缓释制剂
KR20250001767A (ko) 2023-06-29 2025-01-07 재단법인 아산사회복지재단 천식의 분류를 위한 바이오마커 및 이의 용도
WO2025137498A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Matrix tablets of dexpramipexole and methods of manufacturing and use thereof
US20250205206A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
WO2025240942A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246119A1 (en) * 2014-02-21 2015-09-03 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
US20160158205A1 (en) * 2013-07-12 2016-06-09 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1730129B1 (en) * 2004-03-19 2011-01-19 Dipharma Francis S.r.l. Intermediates for the preparation of pramipexole
WO2009120927A2 (en) * 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
WO2013034173A1 (en) * 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9468630B2 (en) * 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2017197360A1 (en) * 2016-05-13 2017-11-16 The Regents Of The University Of California Airway mucus impaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160158205A1 (en) * 2013-07-12 2016-06-09 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US20150246119A1 (en) * 2014-02-21 2015-09-03 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEVEN I DWORETZKY等: ""The targeted eosinophil-lowering effects of dexpramipexole in clinical studies"", 《BLOOD CELLS, MOLECULES & DISEASES》, vol. 63, 16 January 2017 (2017-01-16), pages 62 - 65 *

Also Published As

Publication number Publication date
EP4192453A4 (en) 2024-11-13
US20220040154A1 (en) 2022-02-10
MX2023001140A (es) 2023-05-18
CA3186844A1 (en) 2022-02-10
US20240041841A1 (en) 2024-02-08
EP4192453A1 (en) 2023-06-14
AU2021322255A1 (en) 2023-02-23
CL2023000296A1 (es) 2023-08-25
US20260021077A1 (en) 2026-01-22
AU2021322255A8 (en) 2023-03-30
US20240041840A1 (en) 2024-02-08
IL300357A (en) 2023-04-01
KR20230067604A (ko) 2023-05-16
WO2022031956A1 (en) 2022-02-10
JP2023538278A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
CN116419746A (zh) 右旋普拉克索用于治疗中度至重度哮喘的用途
ES2645368T3 (es) Terapias para mejorar la función pulmonar
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
JP2021107421A (ja) ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
US20250205206A1 (en) Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1241390A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1241390B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090654

Country of ref document: HK